Compugen Ltd. - Ordinary Shares (CGEN)
CGEN moved a median of -0.45% 30 minutes after news, and 0.00% by the close. How CGEN actually reacts to news — the realized, point-in-time move the market made, measured across 112 labeled events over the last three years with zero look-ahead.
CGEN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 112 |
| 30-min | -0.45% | 39% | 112 |
| 60-min | -0.41% | 43% | 112 |
| to close | 0.00% | 49% | 112 |
| Middle 50% of CGEN reactions | -1.25% to +1.20% |
|---|---|
| Median reaction (30-min) | -0.45% |
| Measured reactions | 112 |
Half of all Compugen Ltd. - Ordinary Shares news events land between -1.25% and +1.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CGEN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CGEN's baseline. Nothing else.
Recent CGEN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference | Press release | PR Newswire | +0.22% | -4.31% | |
| Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026 | Press release | PR Newswire | -2.03% | +1.22% | |
| Form 6-K COMPUGEN LTD For: Sep 10 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | +0.39% | +0.39% | |
| Compugen Reports Second Quarter 2026 Results | Press release | PR Newswire | -3.85% | +1.71% | |
| Form 6-K COMPUGEN LTD For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | -3.85% | +1.71% | |
| Form 6-K COMPUGEN LTD For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -3.85% | +1.71% | |
| Compugen to Participate in BTIG Biotechnology Conference 2026 | Press release | PR Newswire | -0.43% | +5.96% | |
| Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 | Press release | PR Newswire | +0.17% | -0.85% | |
| Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress | Press release | PR Newswire | +0.00% | -1.95% | |
| Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 | Press release | PR Newswire | +0.76% | +3.03% | |
| Form EFFECT COMPUGEN LTD | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -3.35% | |
| Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development | Press release | PR Newswire | +0.00% | -3.77% | |
| Compugen Reports First Quarter 2026 Results | Press release | PR Newswire | -2.82% | +0.70% | |
| Form 6-K COMPUGEN LTD For: May 18 | SEC filing · Form 6-K | SEC EDGAR | -2.82% | +0.70% | |
| Form F-3 COMPUGEN LTD | SEC filing · Form F-3 | SEC EDGAR | -2.00% | -0.73% | |
| Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum | Press release | PR Newswire | -2.15% | +1.43% | |
| Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026 | Press release | PR Newswire | +0.00% | -2.58% | |
| Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference | Press release | PR Newswire | +0.00% | +7.36% | |
| Compugen Reports Fourth Quarter and Full Year 2025 Results | Press release | PR Newswire | +6.98% | +18.42% | |
| Compugen to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.00% | +6.55% | |
| Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 | Press release | PR Newswire | +0.00% | +1.82% | |
| Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors | Press release | PR Newswire | -0.59% | -1.76% | |
| Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million | Press release | PR Newswire | -3.33% | -7.88% | |
| Compugen Reports Third Quarter 2025 Results | Press release | PR Newswire | +1.04% | +1.21% | |
| Compugen to Participate in Stifel 2025 Healthcare Conference | Press release | PR Newswire | -0.59% | -5.29% | |
| Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 | Press release | PR Newswire | -3.33% | -5.00% | |
| Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 | Press release | PR Newswire | -2.42% | +13.13% | |
| Compugen to Present at SITC 2025 | Press release | PR Newswire | -4.54% | +1.71% | |
| Compugen to Present Research at the Single Cell Genomics 2025 Conference | Press release | PR Newswire | +0.70% | +2.11% | |
| Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | PR Newswire | +1.03% | -4.11% | |
| Compugen Reports Second Quarter 2025 Results | Press release | PR Newswire | -0.17% | -0.68% | |
| Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 | Press release | PR Newswire | -0.65% | -1.31% | |
| Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 | Press release | PR Newswire | +0.06% | +0.64% | |
| Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer | Press release | PR Newswire | +0.32% | -3.21% | |
| Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences | Press release | PR Newswire | -1.19% | -1.19% | |
| Compugen Reports First Quarter 2025 Results | Press release | PR Newswire | +0.14% | +3.73% | |
| Compugen Announces Leadership Transitions Effective September 2025 | Press release | PR Newswire | -0.76% | +3.05% | |
| Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 | Press release | PR Newswire | -1.01% | -7.43% | |
| Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 | Press release | PR Newswire | -1.59% | -2.55% | |
| Compugen Reports Fourth Quarter and Full Year 2024 Results | Press release | PR Newswire | +0.00% | -4.00% | |
| Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference | Press release | PR Newswire | -1.47% | -9.04% | |
| Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology | Press release | PR Newswire | +0.51% | -0.51% | |
| Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 | Press release | PR Newswire | -0.87% | -0.87% | |
| Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference | Press release | PR Newswire | +3.03% | +2.60% | |
| Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors | Press release | PR Newswire | -3.11% | -1.24% | |
| Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies | Press release | PR Newswire | +1.92% | +3.21% | |
| Compugen Reports Third Quarter 2024 Results | Press release | PR Newswire | +1.49% | -4.76% | |
| Compugen to Participate in Stifel 2024 Healthcare Conference | Press release | PR Newswire | +0.56% | -1.70% | |
| Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 | Press release | PR Newswire | -0.61% | -0.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CGEN section they belong to.
Where else CGEN is measured.
CGEN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GLOBEIMMUNE INC (GBIM) | 113 | 0.00% | 38% |
| Nephros, Inc. (NEPH) | 113 | +1.37% | 58% |
| PetIQ, Inc. - Class A (PETQ) | 112 | 0.00% | 45% |
| PETLIFE PHARMS INC (PTLF) | 112 | 0.00% | 34% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Compugen Ltd. - Ordinary Shares's median reaction calculated?
Every labeled CGEN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 112 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of CGEN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CGEN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.